AZD-1305

AZD-1305

AZD-1305 is an experimental antiarrhythmic agent developed by AstraZeneca. It is primarily used in the treatment of atrial fibrillation and atrial flutter. AZD-1305 has been shown to have a significant effect on the electrical conduction of the heart, specifically by prolonging the action potential duration and refractory period.

Mechanism of Action

AZD-1305 works by inhibiting multiple ion channels in the heart, including the rapid component of the delayed rectifier potassium current (I_Kr), the slow component of the delayed rectifier potassium current (I_Ks), and the inward sodium current (I_Na). This multi-channel blockade results in a prolongation of the action potential duration and refractory period, which can help to prevent the rapid, irregular heartbeats characteristic of atrial fibrillation and atrial flutter.

Clinical Trials

AZD-1305 has undergone several clinical trials to assess its safety and efficacy. In a Phase II trial, the drug was found to be effective in reducing the frequency and severity of atrial fibrillation episodes. However, further research is needed to fully understand the long-term effects and potential side effects of this drug.

Side Effects

As with any drug, AZD-1305 has the potential to cause side effects. These may include nausea, dizziness, and changes in blood pressure. It is important for patients to discuss these potential side effects with their healthcare provider before starting treatment with AZD-1305.

See Also

• Antiarrhythmic agent
• Atrial fibrillation
• Atrial flutter
• Ion channel